Experimental Dermatology · 2013 · 28 citations · 29 references
MedicineCancer BiologyOncologyCancer PharmacologyChemotherapyMolecular OncologyApoptosis ResistanceBcl-2 Family ProteinsChemotherapy ResistanceCytotoxic ChemotherapyMitotic SpindleTherapeutic ResistanceAnti-apoptotic BalanceAnti-apoptotic Bcl-2 Protein InhibitionAnti-apoptotic ProteinsAnti-apoptotic RegulatorsBcl2 InhibitionMitotic Inhibitor ResistanceResistance To Mitotic Inhibitors
Malignant melanoma is refractory to various chemotherapeutics including antitubulin agents such as paclitaxel. Previous studies have suggested a link between βIII-tubulin overexpression and paclitaxel resistance through alterations in the properties of the mitotic spindle. We found that paclitaxel treatment induced temporary mitotic arrest in 7 melanoma cell lines irrespective of the βIII-tubulin level, suggesting that βIII-tubulin had no significant influence on spindle properties. On the other hand, the amount of BCL2, an anti-apoptotic protein, was well correlated with paclitaxel resistance. Treatment of the paclitaxel-resistant cell lines with ABT-737, an inhibitor of BCL2 and BCLxL, or simultaneous knock-down of BCL2 and BCLxL dramatically increased the cells' sensitivity, while knock-down of MCL1, another member of the BCL2 family, had only a minimal effect. Our results suggest that the paclitaxel sensitivity of melanoma cells is attributable to apoptosis susceptibility rather than a change in spindle properties and that BCL2 and BCLxL play a pivotal role in the former.
29
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Ingrid E. Wertz, Saritha Kusam, Cynthia Lam et al. · Nature · 2011 · 810 citations